Ticagrelor: Effects Beyond the P2Y12 Receptor.

Abstract

Platelet P2Y12 receptor inhibitors are crucial in the treatment of patients with acute coronary syndrome or undergoing percutaneous coronary intervention. Ticagrelor is a reversibly binding, potent oral P2Y12 inhibitor that also is a weak inhibitor of the equilibrative nucleoside transporter-1 pathway for cellular adenosine uptake. It is hypothesized that ticagrelor has clinically relevant "off-target" effects, independent of its effect on platelet aggregation and thrombosis. This review considers the pleiotropic effects of ticagrelor and some of the possible mechanisms related to these effects.

Metadata

Item Type:	Article
Authors/Creators:	Sumaya, W. Storey, R.F. https://orcid.org/0000-0002-6677-6229
Copyright, Publisher and Additional Information:	© 2016 Elsevier
Keywords:	Acute coronary syndrome; Adenosine; Inflammation; P2Y(12) antagonist; Ticagrelor
Dates:	Published: January 2017 Published (online): 23 November 2016
Institution:	The University of Sheffield
Academic Units:	The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > Department of Infection, Immunity and Cardiovascular Disease The University of Sheffield > Sheffield Teaching Hospitals
Funding Information:	Funder Grant number BRITISH HEART FOUNDATION FS/15/82/31824
Depositing User:	Symplectic Sheffield
Date Deposited:	14 Dec 2016 10:48
Last Modified:	14 Dec 2016 10:48
Published Version:	http://doi.org/10.1016/j.iccl.2016.08.004
Status:	Published
Publisher:	Elsevier
Refereed:	Yes
Identification Number:	10.1016/j.iccl.2016.08.004
Related URLs:	Author
Open Archives Initiative ID (OAI ID):	oai:eprints.whiterose.ac.uk:109463

CORE (COnnecting REpositories)

Ticagrelor: Effects Beyond the P2Y12 Receptor.

Abstract

Metadata

Download not available

Export

Statistics